STAFFORD, TX, USA I April 02, 2025 I Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its ...

Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades.

Texas Children's Hospital and The University of Texas MD Anderson Cancer Center have announced a collaboration dedicated to ...

Aprea Therapeutics has dosed a subject with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) ...

HPV driven cancers, including HPV+ HNSCC, are characterized by defects in the DDR pathway, making them potentially susceptible to WEE1 inhibition. HPV+ cancers are those where the underlying cause is ...

MONDAY, March 31, 2025 (HealthDay News) -- Surgery might not be needed to treat as many as 60% of early-stage breast cancers, ...

Surgery may not be the best next course of treatment for patients with early-stage breast cancer who had a complete response ...

The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, Fellow of the AACR Academy, as the AACR President-Elect for 2025-2026. Flaherty will become ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial ...

Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal ...

In recognition of their significant achievements to advance cancer care and research, Lauren Byers, M.D., and Paul Scheet, Ph ...